CO6290635A2 - Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua - Google Patents

Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua

Info

Publication number
CO6290635A2
CO6290635A2 CO10098747A CO10098747A CO6290635A2 CO 6290635 A2 CO6290635 A2 CO 6290635A2 CO 10098747 A CO10098747 A CO 10098747A CO 10098747 A CO10098747 A CO 10098747A CO 6290635 A2 CO6290635 A2 CO 6290635A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
water
active ingredients
unit dose
dose form
Prior art date
Application number
CO10098747A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CO6290635A2 publication Critical patent/CO6290635A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición farmacéutica la cual comprende una forma sólida de dosis unitaria la cual comprende: uno o más de los ingredientes activos farmacéuticamente seleccionados de valaciclovir, olanzapina, voriconazol, topotecan, artesunato, amodiaquina, gugulosterona, ramipril, telmisartan, tibolona, atorvastatin, simvastatina, amlodipina, ezetimiba, fenofibrato, tacrolimus, valganciclovir, valsartan, clopidrogel, estradiol, trenbolona, efavirenz, metformina, pseudoefedrina, verapamil, felodipina, ácido valproico/valproato de sodio, mesalamina, hidroclorotiazida, levosulpirida, nelfinavir, cefixima y cefpodoxima proxetil en combinación con un polímero insoluble en agua y/o un polímero soluble en agua. Los métodos para hacer la composición farmacéutica son también descritas.
CO10098747A 2008-01-11 2010-08-11 Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua CO6290635A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN89MU2008 2008-01-11
IN489MU2008 2008-03-10
IN619MU2008 2008-03-24

Publications (1)

Publication Number Publication Date
CO6290635A2 true CO6290635A2 (es) 2011-06-20

Family

ID=40510460

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10098747A CO6290635A2 (es) 2008-01-11 2010-08-11 Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua

Country Status (15)

Country Link
US (1) US20110028456A1 (es)
EP (1) EP2249808A2 (es)
JP (1) JP2011509283A (es)
KR (1) KR20100134557A (es)
CN (1) CN101951891A (es)
AP (1) AP2010005341A0 (es)
AU (1) AU2009203627A1 (es)
BR (1) BRPI0905717A2 (es)
CA (1) CA2712010A1 (es)
CO (1) CO6290635A2 (es)
MX (1) MX2010007645A (es)
PA (1) PA8812601A1 (es)
PE (1) PE20091550A1 (es)
WO (1) WO2009087410A2 (es)
ZA (1) ZA201005015B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
EP2279728A1 (en) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
EP2488029B1 (en) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
MX2013007959A (es) * 2011-01-10 2013-12-06 Celgene Corp Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
CN102188401B (zh) * 2011-05-10 2013-07-03 山东威高药业有限公司 一种非洛地平缓释片及其制备方法
CN102327272B (zh) * 2011-07-14 2013-08-14 海南锦瑞制药股份有限公司 一种口服固体药用组合物及其制备方法
JP6246720B2 (ja) * 2011-10-18 2017-12-13 パーデュー、ファーマ、リミテッド、パートナーシップ アクリルポリマー製剤
WO2013130785A2 (en) * 2012-03-01 2013-09-06 Bristol-Myers Squibb Company Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
RU2759837C2 (ru) 2012-05-31 2021-11-18 Мерк Шарп И Доум Корп. Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
CN103040833A (zh) * 2012-10-10 2013-04-17 盛世泰科生物医药技术(苏州)有限公司 一种伏立康唑的药物组合以及制备方法
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
EA029454B1 (ru) * 2013-11-13 2018-03-30 Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн Новая композиция соединения ацетаминофена без побочного эффекта на печень
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN110179801B (zh) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
GR1008554B (el) * 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
KR101722564B1 (ko) * 2014-09-16 2017-04-03 강원대학교산학협력단 수-난용성 약물을 포함하는 고체분산체
CN104546788B (zh) * 2015-01-13 2018-01-23 上海信谊万象药业股份有限公司 一种辛伐他汀片的制备方法
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
JP2017014119A (ja) * 2015-06-26 2017-01-19 東和薬品株式会社 経口医薬組成物
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US11090272B2 (en) * 2017-01-06 2021-08-17 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
PL3601277T3 (pl) * 2017-03-30 2024-07-08 Merck Patent Gmbh Preparat farmaceutyczny
CN107184559B (zh) * 2017-06-02 2018-07-31 广东赛康制药厂有限公司 一种盐酸二甲双胍缓释片及其制备方法
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
CN110917156A (zh) * 2019-12-18 2020-03-27 乐普制药科技有限公司 一种依折麦布***片及其制备方法
CN111529497A (zh) * 2020-02-11 2020-08-14 兆科（广州）肿瘤药物有限公司 一种吉马替康药物固体分散组合物及其制备方法
WO2022185073A1 (en) * 2021-03-04 2022-09-09 Reckitt Benckiser Health Limited Novel composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0310300D0 (en) * 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
GB0519350D0 (en) * 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
DE602006011485D1 (de) * 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
CA2636339C (en) * 2006-01-19 2014-07-08 Dow Global Technologies Inc. Biologically active composition comprising ethylcellulose

Also Published As

Publication number Publication date
US20110028456A1 (en) 2011-02-03
WO2009087410A2 (en) 2009-07-16
BRPI0905717A2 (pt) 2015-07-14
AP2010005341A0 (en) 2010-08-31
PA8812601A1 (es) 2009-08-26
EP2249808A2 (en) 2010-11-17
CA2712010A1 (en) 2009-07-12
ZA201005015B (en) 2011-03-30
MX2010007645A (es) 2010-11-05
JP2011509283A (ja) 2011-03-24
KR20100134557A (ko) 2010-12-23
CN101951891A (zh) 2011-01-19
AU2009203627A1 (en) 2009-07-16
WO2009087410A3 (en) 2009-09-17
PE20091550A1 (es) 2009-10-03

Similar Documents

Publication Publication Date Title
CO6290635A2 (es) Composición farmaceútica que comprende una forma de dosis unitaria sólida de uno o más ingredientes activos y un polímero insoluble en agua y/o un polímero soluble en agua
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
PH12015501015B1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2009081174A3 (en) Anti - retroviral combination
AR061047A1 (es) Comprimido bicapa para la prevencion de los accidentes cardiovasculares, su uso, y metodo para la prevencion de accidentes cardiovasculares
AR071094A1 (es) Capsula para la prevencion de enfermedades cardiovasculares y su uso
RU2014131238A (ru) Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
UY32749A (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
WO2014114255A3 (zh) 一种定位速释生物粘附剂及应用
RU2014142066A (ru) Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
EP3216450A8 (en) Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof
WO2007110753A3 (en) Extended release dosage forms of metoprolol
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
NI201500027A (es) Formulación de comprimidos compuestos de dos fases que comprenden atorvastatina, irbesartan y carbonato de magnesio.

Legal Events

Date Code Title Description
FA Application withdrawn